Pfizer ends Phase 2 autoimmune study; Lycia aims for $227M IPO

Pfiz­er halts Phase 2 au­toim­mune tri­al: The study was test­ing a pro­gram called PF-06835375 in the rare au­toim­mune dis­or­der pri­ma­ry im­mune throm­bo­cy­tope­nia. The fed­er­al clin­i­cal …